Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- May 11 2020 Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update
- Apr 30 2020 Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis
- Apr 2 2020 Galectin Therapeutics Update on the Impact of COVID-19
- Mar 16 2020 Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update